Connor, Clark & Lunn Investment Management (CC&L)’s Protalix BioTherapeutics PLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$734K Buy
2025
Q1
$1.24M Buy
2024
Q1
Sell
2023
Q4
$126K Sell
2023
Q3
$278K Buy
2023
Q2
$231K Sell
2023
Q1
$333K Buy
2016
Q4
Sell
2016
Q3
$29K Hold
2016
Q2
$32K Sell
2016
Q1
$43K Hold
2015
Q4
$52K Buy
2015
Q3
$45K Buy
2015
Q2
$35K Buy
2013
Q4
Sell
2013
Q3
$235K Buy
2013
Q2
$234K Buy